Wednesday, May 18, 2016

BRIEF-Bristol-Myers Squibb presents two-year overall survival data on Opdivo

* Two-Year overall survival data from two pivotal opdivo

(nivolumab) trials demonstrate sustained benefit in patients

with advanced non-small cell lung cancer

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)